Cargando…

Network Pharmacology-Based Approach to Comparatively Predict the Active Ingredients and Molecular Targets of Compound Xueshuantong Capsule and Hexuemingmu Tablet in the Treatment of Proliferative Diabetic Retinopathy

BACKGROUND: Compound Xueshuantong capsule (CXC) and Hexuemingmu tablet (HXMMT) are two important Chinese patent medicines (CPMs) frequently used to treat proliferative diabetic retinopathy (PDR), especially when complicated with vitreous hemorrhage (VH). However, a network pharmacology approach to u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Hongyan, Xin, Danli, Zhan, Zongyi, Li, Zijing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954618/ https://www.ncbi.nlm.nih.gov/pubmed/33747106 http://dx.doi.org/10.1155/2021/6642600

Ejemplares similares

Exploring the Mechanism of Action Compound-Xueshuantong Capsule in Diabetic Retinopathy Treatment Based on Network Pharmacology
por: Li, Haoran, et al.
Publicado: (2020)

Protective Effects of Fufang Xueshuantong on Diabetic Retinopathy in Rats
por: Duan, Huihui, et al.
Publicado: (2013)

Anti-thrombosis Effects and Mechanisms by Xueshuantong Capsule Under Different Flow Conditions
por: Han, Shuxian, et al.
Publicado: (2019)

A Classification Tree Model with Optical Coherence Tomography Angiography Variables to Screen Early-Stage Diabetic Retinopathy in Diabetic Patients
por: Yao, Hongyan, et al.
Publicado: (2022)

Investigation into the potential mechanism and molecular targets of Fufang Xueshuantong capsule for the treatment of ischemic stroke based on network pharmacology and molecular docking
por: Wang, Lei, et al.
Publicado: (2022)

Network pharmacology and molecular docking study on the active ingredients of qidengmingmu capsule for the treatment of diabetic retinopathy
por: Zhang, Mingxu, et al.
Publicado: (2021)

Chinese medicinal formula Fufang Xueshuantong capsule could inhibit the activity of angiotensin converting enzyme
por: Sheng, Shujing, et al.
Publicado: (2014)

Author Correction: Network pharmacology and molecular docking study on the active ingredients of qidengmingmu capsule for the treatment of diabetic retinopathy
por: Zhang, Mingxu, et al.
Publicado: (2021)

Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration
por: Pan, Hai-Tao, et al.
Publicado: (2020)

Data-Dependent Acquisition and Database-Driven Efficient Peak Annotation for the Comprehensive Profiling and Characterization of the Multicomponents from Compound Xueshuantong Capsule by UHPLC/IM-QTOF-MS
por: Zuo, Tiantian, et al.
Publicado: (2019)

Core Bioactive Components Promoting Blood Circulation in the Traditional Chinese Medicine Compound Xueshuantong Capsule (CXC) Based on the Relevance Analysis between Chemical HPLC Fingerprint and In Vivo Biological Effects
por: Liu, Hong, et al.
Publicado: (2014)

Proteomic analysis revealed the pharmacological mechanism of Xueshuantong injection in preventing early acute myocardial infarction injury
por: Wang, Aoao, et al.
Publicado: (2022)

Identify the Key Active Ingredients and Pharmacological Mechanisms of Compound XiongShao Capsule in Treating Diabetic Peripheral Neuropathy by Network Pharmacology Approach
por: Yu, Meixiang, et al.
Publicado: (2019)

Efficacy and safety of Fufang Xueshuantong Capsules in combination with conventional drugs in the treatment of glaucoma: A meta-analysis and trial sequential analysis
por: Zeng, Zhicheng, et al.
Publicado: (2023)

Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
por: Li, Chunxiao, et al.
Publicado: (2018)

Clinical Efficacy of Xueshuantong plus Urokinase in the Treatment of Sudden Deafness
por: Wang, Yanling, et al.
Publicado: (2022)

Xueshuantong improves cerebral blood perfusion in elderly patients with lacunar infarction★
por: Gui, Qifeng, et al.
Publicado: (2013)

Retracted: Clinical Efficacy of Xueshuantong plus Urokinase in the Treatment of Sudden Deafness
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Intervention of Compound Xueshuantong Capsule on the incidence of heart failure in patients with acute myocardial infarction after PCI based on the combination of disease and syndrome: A multi-center, randomized, double-blind, controlled trial
por: Yang, Xiao-Dan, et al.
Publicado: (2022)

Is preclinical diabetic retinopathy in diabetic nephropathy individuals more severe?
por: Yao, Hongyan, et al.
Publicado: (2023)

Fufang Xueshuantong Improves Diabetic Cardiomyopathy by Regulating the Wnt/β-Catenin Pathway
por: Peng, Meizhong, et al.
Publicado: (2022)

The Effects of Pleiotrophin in Proliferative Diabetic Retinopathy
por: Zhu, Xuemei, et al.
Publicado: (2015)

Identification of the active ingredients and pharmacological effects of Kuntai capsules in the treatment of primary ovarian insufficiency: A review
por: Liu, Feng-Xia, et al.
Publicado: (2023)

Heritability of Proliferative Diabetic Retinopathy
por: Hietala, Kustaa, et al.
Publicado: (2008)

Proliferative diabetic retinopathy in acromegaly
por: Malhotra, Chintan
Publicado: (2010)

Novel therapies for proliferative retinopathies
por: Martinez-Alejo, Juan Manuel, et al.
Publicado: (2022)

Neuroprotective Effect of Xueshuantong for Injection (Lyophilized) in Transient and Permanent Rat Cerebral Ischemia Model
por: Wang, Xumei, et al.
Publicado: (2015)

Efficacy and Safety of Xueshuantong Injection on Acute Cerebral Infarction: Clinical Evidence and GRADE Assessment
por: Lyu, Jian, et al.
Publicado: (2020)

Xueshuantong Improves Functions of Lymphatic Ducts and Modulates Inflammatory Responses in Alzheimer’s Disease Mice
por: Zheng, Rui, et al.
Publicado: (2021)

Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans
por: Chen, Yu-Luan, et al.
Publicado: (2023)

Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy
por: Chernykh, VV, et al.
Publicado: (2015)

Prospective Comparison of Surgery Outcome Between Preoperative and Intraoperative Intravitreal Injection of Ranibizumab for Vitrectomy in Proliferative Diabetic Retinopathy Patients
por: Li, Siying, et al.
Publicado: (2022)

Correlations Between Different Angiogenic and Inflammatory Factors in Vitreous Fluid of Eyes With Proliferative Diabetic Retinopathy
por: Wu, Guanrong, et al.
Publicado: (2021)

Identifying Synergistic Mechanisms of Multiple Ingredients in Shuangbai Tablets against Proteinuria by Virtual Screening and a Network Pharmacology Approach
por: Ma, Xiaoqin, et al.
Publicado: (2020)

Xueshuantong Injection in Treating Deep Venous Thrombosis: A Systematic Review and Trial Sequential Analysis
por: Li, Wenhui, et al.
Publicado: (2021)

Growth Factors in Proliferative Diabetic Retinopathy
por: Khan, Zia Ali, et al.
Publicado: (2003)

Candidate Genes for Proliferative Diabetic Retinopathy
por: Petrovič, Daniel
Publicado: (2013)

Predicting Development of Proliferative Diabetic Retinopathy
por: Harris Nwanyanwu, Kristen, et al.
Publicado: (2013)

Refining vitrectomy for proliferative diabetic retinopathy
por: Chen, San-Ni, et al.
Publicado: (2023)

A network pharmacology based approach for predicting active ingredients and potential mechanism of Lianhuaqingwen capsule in treating COVID-19
por: Zhang, Xiaobo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ot4cnkmcr4bqanh88s2okfl73f